Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Oct;26(4):415–421. doi: 10.1111/j.1365-2125.1988.tb03400.x

The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

R A Wooding-Scott 1, J Smalley 1, J Visco 1, R L Slaughter 1
PMCID: PMC1386563  PMID: 3190991

Abstract

1. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine based upon measurements of total and unbound serum concentrations were determined after a single dose (400 mg) and at steady state (200 mg every 6 h). 2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose. 3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05). 4. The slope of the relationship between quinidine concentration and change in QTc interval was greater at steady state (40.1 +/- 21.7 vs 72.2 +/- 41.7 ms/(mg l-1); P less than 0.05).

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolme P., Otto U. Dose-dependence of the pharmacokinetics of quinidine. Eur J Clin Pharmacol. 1977 Aug 17;12(1):73–76. doi: 10.1007/BF00561409. [DOI] [PubMed] [Google Scholar]
  2. Carliner N. H., Crouthamel W. G., Fisher M. L., Mugmon M. A., Vassar D. L., Narang P. K., Plotnick G. D. Quinidine therapy in hospitalized patients with ventricular arrhythmias. Am Heart J. 1979 Dec;98(6):708–715. doi: 10.1016/0002-8703(79)90467-8. [DOI] [PubMed] [Google Scholar]
  3. Drayer D. E., Lowenthal D. T., Restivo K. M., Schwartz A., Cook C. E., Reidenberg M. M. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther. 1978 Jul;24(1):31–39. doi: 10.1002/cpt197824131. [DOI] [PubMed] [Google Scholar]
  4. Edwards D. J., Axelson J. E., Slaughter R. L., Elvin A. T., Lalka D. Factors affecting quinidine protein binding in humans. J Pharm Sci. 1984 Sep;73(9):1264–1267. doi: 10.1002/jps.2600730919. [DOI] [PubMed] [Google Scholar]
  5. Fremstad D., Nilsen O. G., Storstein L., Amlie J., Jacobsen S. Pharmacokinetics of quinidine related to plasma protein binding in man. Eur J Clin Pharmacol. 1979 Apr 17;15(3):187–192. doi: 10.1007/BF00563104. [DOI] [PubMed] [Google Scholar]
  6. Gey G. O., Levy R. H., Pettet G., Fisher L. Quinidine plasma concentration and exertional arrhythmia. Am Heart J. 1975 Jul;90(1):19–24. doi: 10.1016/0002-8703(75)90252-5. [DOI] [PubMed] [Google Scholar]
  7. Guentert T. W., Holford N. H., Coates P. E., Upton R. A., Riegelman S. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm. 1979 Aug;7(4):315–330. doi: 10.1007/BF01062532. [DOI] [PubMed] [Google Scholar]
  8. Holford N. H., Coates P. E., Guentert T. W., Riegelman S., Sheiner L. B. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. Br J Clin Pharmacol. 1981 Feb;11(2):187–195. doi: 10.1111/j.1365-2125.1981.tb01123.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leroyer R., Jarreau C., Pays M. Specific determination of quinidine and metabolites in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr. 1982 Mar 12;228:366–371. doi: 10.1016/s0378-4347(00)80456-9. [DOI] [PubMed] [Google Scholar]
  10. Ochs H. R., Greenblatt D. J., Woo E., Franke K., Pfeifer H. J., Smith T. W. Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. Am J Cardiol. 1978 Apr;41(4):770–777. doi: 10.1016/0002-9149(78)90830-5. [DOI] [PubMed] [Google Scholar]
  11. Rakhit A., Holford N. H., Guentert T. W., Maloney K., Riegelman S. Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm. 1984 Feb;12(1):1–21. doi: 10.1007/BF01063608. [DOI] [PubMed] [Google Scholar]
  12. Reiter M. J., Higgins S. L., Payne A. G., Mann D. E. Effects of quinidine versus procainamide on the QT interval. Am J Cardiol. 1986 Sep 1;58(6):512–516. doi: 10.1016/0002-9149(86)90025-1. [DOI] [PubMed] [Google Scholar]
  13. Russo J., Jr, Russo M. E., Smith R. A., Pershing L. K. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing. J Clin Pharmacol. 1982 May-Jun;22(5-6):264–270. doi: 10.1002/j.1552-4604.1982.tb02672.x. [DOI] [PubMed] [Google Scholar]
  14. Vozeh S., Uematsu T., Guentert T. W., Ha H. R., Follath F. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther. 1985 May;37(5):575–581. doi: 10.1038/clpt.1985.90. [DOI] [PubMed] [Google Scholar]
  15. Wooding-Scott R. A., Visco J., Slaughter R. L. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state. Am Heart J. 1987 Feb;113(2 Pt 1):302–306. doi: 10.1016/0002-8703(87)90269-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES